Moreover, the integration of this radioimmunotherapeutic approach with other DLL3-targeted modalities, such as bispecific T-cell engagers or chimeric antigen receptor T-cell therapies, presents an intriguing avenue for multimodal treatment strategies in SCLC. The gene discussed is DLL3; the disease is small cell lung carcinoma.